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The impact of obesity in the cardiac lipidomic and its consequences in the cardiac 
damage observed in obese rats 
 
 
El impacto de la obesidad sobre el lipidoma cardiaco y sus consecuencias en el 
daño cardiaco en ratas obesas.  
 
Abstract 
Aims 
To explore the impact of obesity on cardiac lipid profile in rats with diet-induced 
obesity. In addition, we evaluate whether or not the specific changes in lipid species are 
associated with cardiac fibrosis. 
Methods 
Male Wistar rats were fed either a high-fat diet (HFD, 33.5% fat) or standard diet (3.5% 
fat) for 6 weeks. Cardiac lipidomic analysis was performed by liquid chromatography 
tandem mass spectroscopy. 
Results 
HFD rats showed cardiac fibrosis and enhanced levels of cardiac superoxide anion (O2
.
), 
HOMA index, adiposity and plasma leptin and reduction in those of cardiac glucose 
transporter (GLUT 4) as compared with control animals. Cardiac lipidomic analysis 
showed a significant increase of triglycerides, especially those enriched with palmitic, 
stearic and arachidonic acid. An increase in levels of diacilglycerol (DAG) was also 
observed. No changes in cardiac levels of diacylphosphocholine or even a reduction in 
total levels of diacylphosphoethanolamine, diacylphosphoinositol and sphingolipids 
(SM) was observed in HFD as compared with control animals. After adjustment for 
other variables (oxidative stress, HOMA, cardiac hypertrophy), total levels of DAG 
were independent predictors of cardiac fibrosis while the levels of total SM were 
independent predictors of the cardiac levels of GLUT 4. 
Conclusions 
*Manuscrito
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These data suggest that obesity exerts an important impact on cardiac lipid composition, 
although it does not modulate the different species in a similar manner.  Nonetheless, 
these changes are likely to participate in the cardiac damage in the context of obesity 
since total DAG levels can facilitate the development of cardiac fibrosis and SM levels 
predict GLUT4 levels. 
Key words 
Lipidomic, obesity, cardiac remodelling, fibrosis 
 
Resumen 
Objetivos 
Explorar el impacto de la obesidad sobre el perfil lipídico cardiaco en ratas con 
obesidad inducida por dieta.  Se evaluó, además, si estos cambios se asocian con 
fibrosis cardiaca.  
Métodos 
Ratas macho Wistar fueron alimentadas con una dieta con alto contenido en grasa 
(HFD; 33,5% grasa) o con una dieta estándar (3,5% grasa) durante 6 semanas.  El 
análisis del lipidoma cardiaco se realizó mediante cromatografía líquida en tándem con 
espectrofotometría de masas.  
Resultados 
Las ratas HFD presentaron fibrosis cardiaca, estrés oxidativo y un aumento en el índice 
HOMA, adiposidad y los niveles circulantes de leptina así como una reducción en los 
niveles cardiacos del transportador de glucosa (GLUT 4) en comparación con las ratas 
controles.  El análisis del lipidoma cardiaco mostró un aumento de los niveles de 
triglicéridos especialmente los que contenían ácido palmítico, esteárico o araquidónico, 
un incremento en los de diacilglicerol (DAG) aunque no cambios en los de 
diacilfosfocolina y una reducción en los de diacilfosofoetanolamina, diacilfosfoinositol 
o de esfingolipidos (SM) en las ratas HFD en comparación con las control.  Después del 
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ajuste por otras variables (estrés oxidativo, hipertrofia cardiaca, índice HOMA), los 
niveles de DAG fueron predictores independientes de fibrosis cardiaca mientras que los 
de SM fueron de los de niveles de GLUT4.  
Conclusiones 
La obesidad ejerce un impacto importante sobre el lipidoma cardiaco.   Estos cambios 
parecen participar en el daño cardiaco en el contexto de la obesidad ya que los niveles 
de DAG podrían facilitar el desarrollo de fibrosis miocárdica y los de SM los de GLUT 
4.  
Palabras clave 
Lipidomica, obesidad, remodelado cardiaco, fibrosis 
 
Introduction 
Obesity has become a relevant health problem that is reaching epidemic proportions 
worldwide
1
. Obese individuals show a higher risk of cardiovascular morbidity and 
mortality, which has been explained through chronic low-grade inflammation, increased 
oxidative stress and the metabolic alterations associated with obesity which can affect 
cardiac function 
2
. These conditions are linked to excess lipid accumulation not only in 
adipose tissue but also in non-adipose tissues, including the heart, which occurs when 
the storage capacity of adipocytes is exceeded
3
.  
 Lipids are important regulators of cardiac function, not only as the main energy 
substrate for cardiac mitochondrial oxidative metabolism but also by their role in 
membrane phospholipid remodelling, their activity as signalling molecules and ligands 
for nuclear receptors. However, increased myocardial lipid accumulation elicits an 
imbalance between cardiomyocyte fatty acid uptake and fatty acid oxidation
4
, which can 
facilitate the accumulation of cardiotoxic metabolites that can exert deleterious effects 
on the myocardium
5
. Clinical studies with proton magnetic resonance spectroscopy 
have demonstrated that increased intramyocardial triglyceride (TG) accumulation 
occurs before cardiac dysfunction in patients with type 2 diabetes mellitus and 
correlates with body mass index
6,7
. These data supporting a link between cardiac lipid 
accumulation and myocardial dysfunction. Experimental studies
8-11
  have shown that the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 4 
 
accumulation of some lipid species, including diacylglycerol (DAG), lysophospholipids, 
acyl carnitines, ceramides and TGs, can affect cardiomyocyte function and lead to 
cardiac dysfunction. However, the potential mechanisms that link the lipid 
accumulation with the functional alterations are not well established.  
Cardiac fibrosis is an important contributor to heart muscle dysfunction in obesity
12
. 
The excessive extracellular matrix (ECM) deposition arises from the imbalance between 
ECM synthesis and degradation. An exacerbated deposition of ECM components can 
cause an aberrant remodelling that favours functional alterations because a reduced 
relaxing capability of the heart can increase its filling pressure and contribute to 
diastolic dysfunction. However, whether or not changes in lipid profile associated with 
obesity can affect cardiac fibrosis is still undetermined. Therefore, we explore the 
impact of obesity on the heart lipid profile through a lipidomic analysis in rats with diet-
induced obesity as compared with controls. In addition, we evaluate whether the 
specific changes in lipid species could be associated with cardiac fibrosis. 
 
Methods 
Animals 
Male Wistar rats of 150 g (Harlan Ibérica, Barcelona, Spain) received either a standard 
diet (3.5% fat; Harlan Teklad no. TD.2014; n=8) or a high-fat diet (HFD, 33.5% fat; 
Harlan Teklad no. TD.03307, Madison, WI, USA; n=8) for 6 weeks. The Animal Care 
and Use Committee of Universidad Complutense de Madrid approved all experimental 
procedures according to the Spanish Policy for Animal Protection RD53/2013, which 
meets the European Union Directive 2010/63/UE. 
 Body weight was measured once a week. Food and water intake were determined 
throughout the experimental period. Blood pressure (SBP) was estimated basally, at 
mid-study and end-of-study through the use of a tail-cuff plethysmograph (Narco Bio-
Systems, Houston, TX, USA) in unrestrained animals. Serum and plasma were 
collected, fat pads were weighed, and heart was dissected for further analysis at the end 
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of the experimental period. Adiposity index was calculated as sum of fat pad 
weight/(body weight-fat pad weight) x100). 
Evaluation of cardiac structure and function 
Cardiac structure and function were evaluated by transthoracic echocardiography with a 
Philips CX50 (Philips, Netherlands) connected to a L12-3 MHz linear transducer in rats 
anesthetized with isoflurane (2%; Esteve, Barcelona, Spain).  
Measurements of left ventricular (LV) end-diastolic diameter, end- systolic diameter, 
interventricular septum (IVT) and posterior wall thickness (PWT) as well as 
calculations of left ventricular ejection fraction (EF) and LV systolic chamber function 
(pump function) were described elsewhere 
13
. 
Morphological and histological evaluation 
Cardiac tissue samples were dehydrated, embedded in paraffin and cut into 4µm-thick 
sections. Sections were stained with picrosiriusred in in order to detect collagen fibers 
and viewed with polarized light under dark-field optics to detect the birefringence of 
collagen fibers. The area of cardiac interstitial fibrosis was identified as the ratio of 
interstitial fibrosis or collagen deposition to the total tissue area after excluding the 
vessel area from the region of interest. For each sample, 10 to 15 fields were analyzed 
with a 40X objective under transmitted light microscopy (Leica DM 2000; Leica AG, 
Germany). Myocytes (60–80 per animal) with visible nucleus and intact cellular 
membranes were chosen for determination of cross-sectional area in cardiac sections 
stained with hematoxylin and eosin.  
Western blotting 
Cardiac tissue lysates were separated by SDS-PAGE and transferred to 0.2µM 
nitrocellulose membranes (Bio-Rad Laboratories, Germany) Blots were incubated with 
antibodies against glucose transporter4 (GLUT4) (Santa Cruz Biotechnology Inc, 
Heidelberg, Germany). Bound antibodies were detected after incubation with an HRP-
conjugated IgG and using the Super Signal West Dura Extended Duration Substrate 
(Thermo Fisher Scientific Inc, Waltham, MA, USA). Equal loading of protein in each 
lane was verified by β-actin (Sigma). 
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Detection of superoxide anion production  
The oxidative fluorescent dye dihydroethidium (DHE; Invitrogen, Grand Island, NY, 
USA) was used to evaluate superoxide anion (O2
.-
) production. Cardiac and aorta tissue 
samples were embedded in tissue-freezing medium. 14-µm thick sections were then cut 
with a cryostat, placed onto glass microscope slides and washed briefly in Krebs-
HEPES buffer (in mmol/L: NaCl 130, KCl 5.6, CaCl2 2, MgCl2 0.24, HEPES 8.3, 
glucose 11, pH 7.4). Slides were then incubated with DHE (5x10
-3
mmol/L) for 30 min 
at 37ºC in a light-protected humidified chamber. Slides were subsequently washed with 
warm phosphate-buffered. Cardiac images were viewed by fluorescent laser scanning 
microscope (40X objective in a Leica DMI 3000 microscope) (Ex561 nm and Em610 
nm) using the same imaging settings in each case. Three separate histological sections 
and four different fields in each section per animal were quantified and averaged for 
each experimental condition. The mean fluorescence densities in the target region were 
calculated. Results are expressed as an n-fold increase over the values of the control 
group.  
Lipidomic analysis 
Myocardial lipids were extracted and analyzed by ultrahigh performance liquid 
chromatography coupled to time-of-flight mass spectroscopy (UPLC-QToF-MS) using 
an Acquity UPLC System and a SYNAPT HDMS G2 (Waters, Manchester, UK) with 
electrospray ionization. Extraction of lipids was carried out from cardiac homogenates 
in methanol:chloroform mixture (1:2, v/v) and split into two aliquots. One aliquot was 
evaporated to dryness and the pellet re-suspended in acetone:2-propanol:ethanol (3:4:3, 
v/v/v) and used for TGs measurement. The other aliquot was evaporated to dryness and 
the pellet re-suspended in methanol:water (9:1, v/v/v) and used for phospholipids 
(PPLs) measurement. Extracts were kept at -80ºC until analysis. Mass spectrometric 
analysis of TGs was performed in positive mode (ESI+) using the parameters that 
follow: capillary, 0.8 kV; sampling cone, 15 V; source temperature, 90 ºC; desolvation 
temperature, 280 ºC; cone gas, 40 L/h; and desolvation gas, 700 L/h. Data were 
acquired with the software MassLynx at a rate of 5 scans/s within the range 0-18 min, 
and m/z 100-1200 Da for the low-energy function and m/z 100-900 Da for the high-
energy function (MS
E
 method, trap collision energy 30 V). LC and MS methods were 
optimized using the commercial standards TG (18:2/18:2/18:2) and TG 
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(16:0/16:0/16:0). These standards were also used to draw calibration curves for 
quantification. Mass spectrometric analysis  of PPLs was fitted as follows: capillary, 0.9 
kV; sampling cone, 18 V; source temperature, 90 ºC; desolvation temperature, 320 ºC; 
cone gas, 45 L/h; and desolvation gas, 900 L/h. Data were acquired with the software 
MassLynx at a rate of 5 scans/s within the range 0-12 min and 100-1200 Da m/z for the 
low-energy function, and 50-900 Da m/z for the high-energy function (MS
E
 method, 
trap collision energy 30 V), with ionization in positive mode (ESI+) for detection of 
diacylphosphatidylcholines (PCs), ceramides (Cer) and sphingomyelins (SM),  and with 
ionization in negative mode (ESI-) for detection of other phospholipids, which were 
diacylphosphatidylethanolamine (PE), diacylphosphatidylinositol (PI), 
diacylphosphatidylglycerol (PG), and phosphatidic acids (PA). External commercial 
standards, namely PI (8:0/8:0), PG (14:0/14:0), PE (12:0/12:0), PC (10:0/10:0) and PA 
(14:0/14:0) were purchased from Cayman Chemical (Michigan, USA) and used for 
method optimization and quantification. 
Up to three different chromatograms were manually checked for mass spectral peak 
identification where possible. Within each chromatographic point, m/z values with an 
intensity >= 700 were also checked for it in order to afford a defined chromatographic 
peak (Extracted Ion Chromatogram, EIC); if positive, the elemental composition tool 
was then used to determine all the possible chemical compositions (CnHmOpNsPrSt) that 
were compatible with the isotopic distribution (M, M+1, M+2 and M+3 peaks) of a 
given m/z value. Using LipidMaps, Metlin, CheBI, LipidBank and KEGG databases, a 
certain elemental composition was examined for possible known compounds. Where 
possible, acyl chains were identified by data from the high-energy function 
(fragmentation). As well, specific fragments in the high energy function (MS
E
) were 
considered for identification, in particular m/z 184.07 for PCs and SMs in positive 
ionization mode.  
Statistical Analysis 
Data are expressed as mean±SEM. Normality of distributions was verified by means of 
the Kolmogorov-Smirnov test. Data were analyzed using an unpaired Student's t-test to 
assess specific differences among groups using GraphPad Software Inc. (San Diego, 
CA, USA). Pearson correlation analysis was used to examine association among 
different variables. To find the factors associated with cardiac fibrosis or protein levels 
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of GLUT4, the β-correlation coefficients (slope or mean difference, along with their 
95% CIs) were obtained using a linear regression model. The predetermined 
significance level was P < 0.05. 
Results 
Experimental animals showed a progressive increase in body weight that was larger in 
the animals fed a HFD than in those fed a control diet. A similar increase was observed 
in adiposity index (Table 1).  Our data demonstrated a significant increase in relative 
heart weight in obese animals as compared with the control group (Table 1). The HFD 
group showed also an increase in HOMA index (three-fold; Table 1), which suggests 
insulin resistance. The echocardiographic values for both structural features and left 
ventricular systolic function were similar in both groups (Table 1). No differences were 
found in systolic blood pressure at the end of the experiment between both groups 
(Table 1). 
Diet-induced obese animals showed an increase (2.5 fold) in cardiac interstitial fibrosis 
in comparison to controls as demonstrated by the higher collagen volume fraction in the 
HFD group (Figures 1A-1B). This increase was mainly due to the cross-linked collagen, 
which increased 2.9 fold as compared with control group (Figures 1C-1D). No 
differences were observed in cardiac myocyte cross-sectional area among any of the 
groups (data not shown).  
The cardiovascular levels of O2
.−
 in obese animals were higher than those observed in 
control animals as suggested by the higher fluorescence intensity in myocardial tissue 
sections incubated with DHE (Figures 1E-1F). In agreement with previously reported 
data in clinical and experimental studies, obese animals presented higher plasma leptin 
levels as compared to normoweight rats (Table 1). In fact, the cardiac protein levels of 
GLUT4 were reduced in HFD as compared to control rats (Figure 2). 
HFD rats showed an increase (16%) in the cardiac lipid content as compared with 
control animals, although it did not reach statistical significance. The cardiac lipidomic 
analysis detected overall 205 individual lipid subspecies over 12 different classes 
encompassing, among others, TG, DAG, SM, CER and PPLs.  The analysis showed a 
relevant alteration in the cardiac lipid profile between HFD and control rats with 
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changes identified in more than 50% of all species, although all lipid components are 
not affected in the same manner. The main lipid component was the PPLs, with PC and 
PE being the most abundant. Although no significant differences were observed 
between total levels of PC between both groups (Figure 3A), a significant increase was 
observed in those species with 20:4 acyl chain, (p<0.01; Figure 3A). By contrast, total 
cardiac PE levels were reduced (Figure 3; p<0.05), a fact mainly due to the reduction of 
the levels of PE containing palmitic acid (p<0.05), PE/PC ratio was consequently lower 
in HFD rats than in controls (2.3±0.04 vs 2.7±0.1; p<0.05; respectively). In addition, an 
increase was observed in lysoPE levels in HFD as compared with control animals. This 
increase was also observed in total lysoPC (LPC) species in obese rats versus 
normoweight animals (p<0.01). This increase was a consequence of the rise (p<0.01) 
observed in those animals of the major component, the LPC (20:4) (Figure 3A). Both PI 
and diacylphosphatidylserine (PS) species were also detected although at lower levels. 
However, the impact of the HFD was different in PI and PS: no changes in total levels 
of PS but a reduction (p<0.05; Figure 3) in total PI levels, the reduction in PI being 
mainly a consequence of the drop in PI (18:0/24:0), which was one of the most 
abundant PI species detected in this study (Figure 3A).  
Total TG levels were increased (p<0.01; Figure 3A) in HFD rats as compared with 
control animals by 2.7-fold. This increase was mainly due to those TG containing 
palmitic or stearic acids (Figures 3B-3C). In fact, 78% and 100%, respectively, of the 
detected TG species of each type were elevated, with the TG 50:1 (16:0/16:0/18:1), 52:1 
(16:0/18:0/18:1) and 52:2 (16:0/18:1/18:1) being the most abundant species (data not 
shown). The overall TG analysis showed that, as compared with control animals, the 
levels of those containing only saturated fatty acids were higher (3.8-fold increase) in 
HFD without significant changes in the levels of species containing only 
polyunsaturated or monounsaturated fatty acids. HFD rats also exhibited an increase of 
7.6 fold in cardiac TG arachidonic acid (20:4) as acyl chain (p<0.01; Figure 3A).  
Four species of DAG were detected in HFD group but only two of them were found in 
the heart of the control group (DAG 38:6; DG 42:5), which were the most abundant 
DAG species. Animals fed a HFD showed an increase in total DAG levels (0.85 folds; 
p<0.05; Figure 3A), since 3 (DAG 50:0; DAG 52:1; DAG 42:5) of the 4 species 
detected were significantly elevated in HFD as compared with animals fed a control 
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diet. In fact, the DAG containing C20:4 increased 0.6-fold (p<0.05; Figure 3A) in HFD 
group as compared with control group. SM represented only around 5% of the cardiac 
lipids in control animals, and this content dropped to 1.4% in HFD animals (p<0.01) 
because of the drastic decrease (p<0.001) observed in the main SM specie detected in 
this study(SM (d18:1/16:0). However, no reduction was observed in the levels of those 
SM with 20:4 (Figure 3A). No differences were observed in levels of either 
sphingosine-1-phosphate (data not shown), carnitine or in the two detected species of 
ceramide between both groups (Figure 3A).  As shown in table 2, adiposity index was 
correlated with levels of leptin, HOMA index, total lipids, arachidonic acid  containing 
TGs and LPC levels. A negative correlation was found between adiposity and total 
levels of SM and PI. HOMA index was positively correlated with leptin levels and 
C20:4-containing TG content but a negative correlation was found of HOMA index to 
levels of PI and PE (table 2).    
 
In order to   examine the relationship between cardiac lipid profile changes and cardiac 
fibrosis or cardiac levels of GLUT4, a linear regression analysis was performed. After 
adjustment for other variables which could affect cardiac fibrosis (HOMA index, ROS,  
and cardiac hypertrophy), it was found that total level of DAG could be considered an 
independent predictor of cardiac fibrosis (odds ratio 0.602; 95% CI, 0.012-0.683; 
p=0.04) whereas the level of total SM was shown to be an independent predictor of the 
cardiac level of GLUT 4 (odds ratio 28.18; 95% CI, 14.994-41.37; p=0 0.001) 
 
Discussion 
Cardiac lipotoxicity has been associated with cardiac functional alterations in the 
context of obesity, this fact suggesting that accumulation of lipids may exert a toxic 
effect on the myocardium
4,14
. Even though cardiac lipotoxicity has been identified to 
accompany increases in TG levels, it is likely that the content and composition of other 
different lipid species are also altered and this imbalance can contribute to the cardiac 
damage associated with obesity, as well.  In this study, we report a significant lipidomic 
remodelling in the heart of rats with diet-induced obesity with regard to normally fed 
rats, the remodelling involving more than 50% of the lipid species detected in the heart. 
These changes, although affecting cardiac TG to a significant degree, also modify other 
species, including DAGs, SMs, PIs and LPCs, and this feature suggests that obesity has 
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an effect on lipid content in the heart more than the one which had been foreseen. These 
changes seem to be relevant because of the cardiac consequences of obesity since total 
DAG content seems to be a determinant factor for cardiac fibrosis, as does SM levels 
for the cardiac levels of GLUT 4; this suggests its potential role in the cardiac metabolic 
alterations in the context of obesity. 
The data show that the increase in body weight observed in the model of diet-induced 
obesity (HFD animals) was associated with an important impact on cardiac lipid 
composition, with about 59% of the detected lipid species exhibiting a modified 
content. However, the change trends were species-specific, which resulted in only a 
slight increase in total lipids (16%) in HFD rats as compared with controls because of 
the increase in some species counteracted the decrease in other species. TGs were the 
main lipid class affected in regard to their content and profile, especially those 
containing stearic and palmitic acid were shown to have levels increased up to 8- and 
4.5-fold, respectively, in HFD as compared with controls; this fact closely reflects the 
fatty acid composition of the diet. Indeed, significant correlations were found between 
adiposity, it being measured by the index of obesity, and levels of either total TG or 
those enriched with arachidonic and palmitic acids, such correlations supporting a close 
link between excess caloric intake and TG accumulation in the myocardium. These data 
are in agreement with those reported in previous studies, which demonstrated that 
cardiac or circulating TG levels were elevated in both obese patients and models of diet-
induced obesity
3,15-18
.  More importantly, the changes observed in TG species in obese 
animals indicate that it is due to a profile more prone to cardiovascular complications. 
An imbalance due to either increased lipid uptake or decreased lipid oxidation has been 
proposed as the main cause underlying lipid accumulation. This idea is supported by 
studies in genetically modified mice, which affect a variety of components involved in 
lipid transport, storage, and metabolism
19-23
. An enhanced lipid uptake has been 
suggested as a determinat factor involved in cardiac lipotoxicity in clinical studies in 
obese patients
24
. In addition, it has been suggested that other lipid species could be 
facilitating heart TG accumulation. In this regard, Lim and Bodmer  have shown that a 
reduction in PE levels through the modulation of the activity of the sterol regulatory 
element binding protein could facilitate lipogenesis in the heart of the model of easily-
shocked Drosophila
25
. Supporting this concept is the fact that our data showed a 
negative correlation between cardiac TG levels and those of PE (data not shown). 
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Although different mechanisms have been bound to TG accumulation and insulin 
resistance
26-28
, some studies have suggested that TG are metabolically inactive since 
accumulation of TG has been observed in the muscle of insulin-sensitive women and 
athletes
29
. Similarly, plasma TG is not associated with insulin resistance in overweight 
and obese patients
30
.  However, our data did not allow us to reach any conclusion 
regarding this feature because it is difficult to consider that changes in cardiac lipid 
species can allow for it to underlie the observed systemic insulin resistance. However, 
our data show that total SM levels, and especially the levels of SM(18:1/16:0), were 
independent predictors of  GLUT4 cardiac levels, supporting previous data that suggest 
a positive role for SMs in insulin sensitivity in patients
31
. Similarly, it has been shown 
that dietary SM improves metabolic complications associated with diet-induced obesity 
in mice
32
.  
 
Cardiac interstitial fibrosis is a common feature in the context of obesity, which 
contributes to the pathogenesis of diastolic dysfunction
12,33
. As previously 
reported
17,18,34
, HFD animals show an increase in interstitial fibrosis, although no 
functional changes in cardiac function were observed, probably due to the relatively 
short-time of evolution of obesity. The increase in interstitial fibrosis is mainly due to 
crosslinking collagen that is less prone to degradation. We have recently reported that 
the administration of an inhibitor of the activity of lysyl oxidase that catalyses the 
covalent cross-link of collagen and elastin fibers
35
 reduced cardiac fibrosis in rats with 
diet-induced obesity
34
. A variety of factors has been involved in the development of 
cardiac fibrosis, including adipokines such as leptin. In fact, this role involved the 
activation of oxidative stress, engaging downstream events, which mediate the 
activation of PI3K/Akt pathway and, consequently, the production of end effectors. 
Such effectors include TGF-β, CTGF and galectin-3, which are mainly responsible for 
the final synthesis of ECM in cardiac myofibroblasts, the main factor responsible for 
fibrosis
36,37
. Cardiac fibrosis can cause an aberrant remodelling that favours functional 
alterations, since a reduced relaxing capability of the heart can increase its filling 
pressure and contribute to diastolic dysfunction. The general concept that lipotoxicity 
can participate in cardiac fibrosis and functional alterations is widely accepted
19,38-42
. 
However, the potential mechanism involved is not well established. The present data 
further extend this concept because it shows that the levels of DAG can predict those of 
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cardiac interstitial fibrosis in rats. In agreement with this concept, it has been reported 
that the cardiac overexpression of cardiac-specific diacylglycerol kinase, an enzyme that 
negatively controls the cellular levels of DAG, reduces cardiac fibrosis and improved 
ventricular remodelling in mice with myocardial infarction, diabetes or aortic 
constriction 
43-45
. 
 
The potential underlying mechanisms are not well established but different data have 
linked DAG to cardiac lipotoxicity
10,46,47
. DAGs are intracellular second messengers 
capable of increasing the activity of protein kinase C (PKC), which promotes cardiac 
fibrosis and heart failure
48-51
 through the activation of galectin-3 and oxidative 
stress
48
,
51
. Therefore, activation of these factor which we have previously reported can 
participate in the cardiac fibrosis observed in rats fed a HFD
18
 could be a potential 
mediator through which DAG can participate in the cardiac fibrosis in the context of 
obesity. Interestingly, changes in the DAG fatty acid composition result in translocation 
and activation of distinct PKC isoenzymes
52,53
. Thus, it has been shown that 20:4ω-6 
enriched DAG are more efficient that those with 20:5ω-3 or 22:6ω-3 in activating 
PKCδ, PKCε and PKCα. On the contrary, activation of PKCβI by DAG-containing 
arachidonic acid was significantly lower than that induced by the DAGs containing ω-3 
PUFAs. Given that PKC isozymes play different roles, even opposites, in specific 
aspects of cardiac remodelling in HFD, the differential activation of PKC isoforms 
possibly leads to different pathophysiological effects. This phenomenon may be 
implicated in the influence of ω-3 or ω-6 polyunsaturated fatty acids in health and 
disease. Thus, our findings that DAG containing 20:4ω-6 is increased in HFD group 
might be linked to an activation of PKC isotypes such as PKCδ, PKCε and PKCα. In 
agreement, it has been reported that these isoforms can mediate cardiac fibroblast 
proliferation and collagen production
54,55
, and activation of PKCδ has been associated to 
increased cardiac damage
56
. Moreover, it has been reported that the presence of cardiac 
DAG enriched with ω-3 is associated with a reduction of PKCε and PKCα 
translocation
53
. 
 
Finally, it is worth mentioning that other observed changes could be relevant to 
different aspects of the cardiac function that were not evaluated in the study, such as the 
reduction in the ratio PE/PC. The levels of PC and PE are key regulators of the 
membrane integrity as well as of its biophysical properties, such as curvature and 
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rigidity, which influence protein functions. Thus, it has been recently reported that the 
activity of GLUT4 is controlled by the membrane PPLs composition
57
. The lipid 
components of the membrane can impact not only cell function but also mitochondrial 
function, since PE and PC are the predominant PPLS in mitochondrial membrane
58
. 
Reductions in PI levels, which play important roles in lipid signaling, cell signaling and 
membrane trafficking, could also be relevant. 
 
In summary, these data suggest that obesity exerts an important impact on cardiac lipid 
composition, although it does not modulate the different species in a similar manner.  
While an increase in TG and DAG-species was observed, PPLs, the main lipid 
component in the heart either does not change (PC, PS) or decrease (PE, PI). These 
changes can participate in the cardiac damage in the context of obesity. Specifically, 
DAG can facilitate the development of cardiac fibrosis and SM levels can modulate 
cardiac GLUT4 levels and, in consequence, the decrease in SM observed in HFD rats 
could facilitate the changes in the metabolic substrate use for myocardium that occurs in 
obesity. Although further work is warranted to better understand the entire spectrum of 
the cardiac functional consequences of the alterations on the lipid profile, the data 
provide an understanding of these changes and an insight into their underlying 
complexity.  
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Table 1. Body weight, adiposity, relative heart weight, leptin levels, HOMA index, 
echocardiographic parameters and systolic blood pressure in control rats and rats 
fed a high fat diet (HFD). 
 CT HFD 
Body Weight (g) 329.2±7.5 371.2±3.9*** 
Adiposity index 2.7±0.29 6.6±0.62*** 
HW/TL 
(mg/cm tibia) 
 205.1±7.6 243.2±8.4** 
Leptin levels (ng/ml)  12.5±1.8 82.4±25.1* 
HOMA Index  2.4±0.27 6.7±1.59* 
IVT (mm) 1.73±0.14 1.79±0.2 
PWT(mm) 1.81±0.2 1.74±0.2 
EDD (mm) 5.2±0.43 4.9±0.4 
ESD (mm) 2.6±0.25 2.8±0.24 
EF (%) 85.3±3.5 84.8±3.2 
FS (%) 46.1±0.4 46.9±2.9 
SBP (mmHg) 122.9±3.4 124.8±3.3 
 
HW: heart weight; TL: tibia length; HOMA index: the homeostasis model 
assessment; IVT: interventricular septum thickness; PWT: posterior wall thickness; 
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EDD: end-diastolic diameter; ESD: end-systolic diameter; EF: ejection fraction; FS: 
fractional shortening; SBP: systolic blood pressure. Data values represent mean ± S.E.M 
of 6 animals. * p<0.05; ** p<0.01; *** p<0.001 vs. control group. 
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Table 2. Associations found between adiposity index and HOMA Index and leptin 
plasma levels and cardiac lipid levels in control rats and rats fed a high fat diet 
(HFD). 
 r P value 
Adiposity 
HOMA Index 
 
0.706 
 
0.023 
Leptin 0.805 0.005 
Total Lipids 0.808 0.005 
TG 20:4 0.801 0.005 
LPC 0.832 0.003 
SM -0.691 0.027 
Total PI -0.716 0.02 
HOMA Index 
Leptin 
 
 
0.891 
 
0.001 
TG 20:4 0.694 0.026 
PE -0.847 0.008 
PI -0.825 0.003 
 
 
HOMA index: the homeostasis model assessment; TG: Triglycerides; SM: sphingolipid; 
PE: phosphoethanolamine; PI: phosphoinositol 
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Figure legends 
Figure 1. Consequences of a high fat diet in the heart of rats. (A): Collagen volume 
fraction (CVF) and (B) Representative microphotographs of myocardial sections 
staining with picrosirius red examined by light microscopy (magnification 40X) in heart 
from control rats (CT) and rats fed a high-fat diet (HFD). (C) Percentage of cross-linked 
collagen and (D) Representative microphotographs of myocardial sections staining with 
picrosirius red examined by polarized light microscopy  (magnification 40X) in heart 
from control rats (CT) and rats fed a high-fat diet (HFD).  (E)  Quantification of 
superoxide anions production in hearts from control rats (CT) and rats fed a high-fat 
diet (HFD) and (F) representative microphotographs of myocardial sections labeled 
with the oxidative dye hydroethidine by fluorescence microscopy (magnification 40X). 
Scale bar: 50 µm. Values are mean±SEM of 8 animals. *p<0.05; ***p<0.001 vs control. 
Figure 2. Consequences of a high fat diet in the cardiac levels of GLUT 4 in rats. 
Protein levels of GLUT4.  Quantification of band intensities was measured by 
densitometry and normalized to respective α-tubulin. Values are mean±SEM of 8 
animals. *p<0.05  vs control. *p<0.05; ***p<0.001 vs control. 
Figure 3. Consequences of a high fat diet in the cardiac lipidome of rats. (A) 
Changes in   lipid levels in heart from control rats (CT) and rats fed a high-fat diet 
(HFD). (B) Levels of triglycerides enriched with palmitic acid (16:0). (C) Levels of 
triglycerides enriched with stearic acid (18:0); and (D) Levels of triglycerides enriched 
with arachidonic acid (20:4) in heart from control rats (CT) and rats fed a high-fat diet 
(HFD). Values are mean±SEM of 6 animals. **p<0.01vs control. 
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